ReviewBiotechnology letters2022
Current trends in biopharmaceuticals production in Escherichia coli.
Review in Biotechnology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- Transposon-based genome editing of industrial microorganisms: advances, challenges, and prospects.Synthetic and systems biotechnology · 2026Review
- Application of dielectric spectroscopy combined with simple linear and multivariate modelling for in-line monitoring of biomass concentration in E. coli cultures.Bioprocess and biosystems engineering · 2026Article
- Overcoming cellular secretion bottlenecks: advanced secretion engineering and molecular tailoring for next-generation microbial α-amylases with enhanced industrial performance.World journal of microbiology & biotechnology · 2026Review
- Review
- Low inducer concentrations at 10 °C promotes soluble recombinant expression of Aedes aegypti mosquito midgut proteases in E. coli.Microbial cell factories · 2026Article
- Modulating 6 S RNA improves recombinant protein yield in Escherichia coli at lower temperatures.World journal of microbiology & biotechnology · 2026Article
- Biological Profiling of Postbiotics of Lactobacillus plantarum: Antibacterial, Antioxidant, and Cytotoxic Properties Under In Vitro and Food Circumstances.Probiotics and antimicrobial proteins · 2026Article
- Protein nanoparticles assemble in plants, display antigenic viral peptides, and produce an epitope-specific immune response.The FEBS journal · 2026Article
- Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization.Molecular biotechnology · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Deep learning on protein language model embeddings unlocks accurate prediction of protein solubility.Frontiers in microbiology · 2026Article
- Low Inducer Concentrations at 10°C Promotes Soluble Recombinant Expression of Aedes aegypti Mosquito Midgut Proteases in E. coli.Research square · 2025Article
- Modulation of Aging Diseases via RAGE Targets: A Dietary Intervention Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Ty retrotransposon element based multiple integration toolkit forSynthetic and systems biotechnology · 2025Article
- Ministring DNA (msDNA): a novel linear covalently-closed DNA with enhanced stability for gene and cell therapy applications.Scientific reports · 2025Article
- Novel processes to obtain pneumococcal surface proteins for vaccines.Applied microbiology and biotechnology · 2025Review
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- BeyondChemical reviews · 2025Review
- Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Since the manufacture of the first biotech product for a fledgling biopharmaceutical industry in 1982, Escherichia coli, has played an important role in the industrial production of recombinant proteins. It is now 40 years since the introduction of Humulin® for the treatment of diabetes. E. coli remains an important production host, its use as a cell factory is well established and it has become the most popular expression platform particularly for non-glycosylated therapeutic proteins. A number of significant inherent obstacles in the use of prokaryotic expression systems to produce biologics has always restricted production. These include codon usage, the absence of post-translational modifications and proteolytic processing at the cell envelope. In this review, we reflect on the contribution that this model organism has made in the production of new biotech products for human medicine. This will include new advancements in the E. coli expression system to meet the biotechnology industry requirements, such as novel engineered strains to glycosylate heterologous proteins, add disulphide bonds and express complex proteins. The biopharmaceutical market is growing rapidly, with two production systems competing for market dominance: mammalian cells and microorganisms. In the past 10 years, with increased growth of antibody-based therapies, mammalian hosts particularly CHO cells have dominated. However, with new antibody like scaffolds and mimetics emerging as future proteins of interest, E. coli has again the opportunity to be the selected as the production system of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.